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Abstract
Background: Adrenocortical carcinoma (ACC) is a rare tumor in which prognostic factors are still not well
established. Programmed Death Ligand-1 (PD-L1) expression in ACC and its association with clinico-pathological
features and survival outcomes are unknown.
Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 28 patients with ACC. PD-L1
expression was evaluated by immunohistochemistry (IHC) in both tumor cell membrane and tumor infiltrating
mononuclear cells (TIMC). PD-L1 positivity on tumor cells was defined as ≥5% tumor cell membrane staining. TIMC
were evaluated by IHC using a CD45 monoclonal antibody. For PD-L1 expression in TIMC, a combined score based
on the extent of infiltrates and percentage of positive cells was developed. Any score greater that zero was
considered PD-L1 positive. Baseline clinico-pathological characteristics and follow up data were retrospectively
collected. Comparisons between PD-L1 expression and clinico-pathological features were evaluated using
unpaired t-test and Fisher’s exact test. Kaplan-Meier method and log-rank test were used to assess association
between PD-L1 expression and 5-year overall survival (OS).
Results: Among 28 patients with surgically treated ACC, 3 (10.7%) were considered PD-L1 positive on tumor cell
membrane. On the other hand, PD-L1 expression in TIMC was performed in 27 specimens and PD-L1 positive
staining was observed in 19 (70.4%) patients. PD-L1 positivity in either tumor cell membrane or TIMC was not
significantly associated with higher stage at diagnosis, higher tumor grade, excessive hormone secretion, or OS.
Conclusions: PD-L1 expression can exist in ACC in both tumor cell membrane and TIMC with no relationship to
clinico-pathologic parameters or survival.
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Background
Adrenocortical carcinoma (ACC) is a rare and highly
lethal malignancy arising from the adrenal cortex. In
the United States, around 0.7-2 new cases per million
are estimated every year [1,2]. Overall, ACC carries a
poor prognosis with the most consistent prognostic
factor being tumor stage at the time of diagnosis [3].
Unfortunately, retrospective studies have reported a 5-
year survival rate of 24% for stage III and 0% for stage
IV disease [4].
Complete surgical resection remains the only chance
of cure for patients with early-stage disease (stage I and
II). When feasible, resection is the mainstay of therapy,
even for patients with locally advanced disease. Not
without controversy, some studies suggest that adjuvant
mitotane may improve clinical outcomes [5]. However,
despite aggressive management, close to 80% of surgi-
cally treated patients will develop subsequent metastatic
disease [6].
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The management of metastatic disease is challenging
and disappointing results have been reported with the
few available systemic therapeutic options [7]. Despite
no statistically significant impact on overall survival
(OS), results from the First International Randomized
Trial in Locally Advanced and Metastatic ACC Treatment
(FIRM-ACT) study have provided most consistent evi-
dence for systemic treatment in advanced ACC [8]. This
collaborative effort evaluated two different widely recom-
mended regimens based on small phase II clinical trials
[9,10]: mitotane plus a combination of etoposide, doxo-
rubicin, and cisplatin (M/EDP) or mitotane plus strepto-
zocin (SM). Patients who were treated with M/EDP had a
significantly longer progression-free survival (PFS) com-
pared with those who received SM (5.0 vs 2.1 months).
Subsequent systemic options after progression on M/EDP
or SM include gemcitabine plus capecitabine or metro-
nomic 5-fluouracil which showed some clinical activity in
a phase II clinical trial [11].
The biology underlying ACC is poorly understood
[12]. So far, small studies have failed to demonstrate
clinical benefit with targeted therapies blocking the
epidermal growth factor receptor (EGFR), vascular endo-
thelial growth factor (VEGF), mammalian target of rapa-
mycin (mTOR), insulin-like growth factor 1 receptor
(IGF-1R), or fibroblast growth factor receptor (FDFR)
pathways in advanced disease, and no biomarkers have
been established as predictors of survival or response to
these agents [13-18]. The Tumor Cancer Genome Atlas is
ongoing for ACC. This initiative will provide a compre-
hensive molecular characterization of this disease and
may help to identify targets for drug development or a
prognostic signature for risk stratification.
The current progress in understanding how the im-
mune system can modulate tumor progression or effect-
ive responses against cancer is unfolding [19]. Immune
checkpoints, like programmed death-1 (PD-1) and its
ligand PD-L1, have been described as key regulators of
T cell responses, and blocking the PD-1/PD-L1 axis
using monoclonal antibodies has resulted in promising
results in different malignancies [20]. Notably, in some
series, levels of PD-L1 expression have correlated with
clinical outcome [21,22]. However, the prognostic impact
of PD-L1 expression still needs to be defined in many
tumor types including ACC.
In this study, our goal is to characterize PD-L1 expres-
sion in ACC tissues and to correlate levels of PD-L1 ex-
pression with clinico-pathological features as well as
survival outcomes.
Results
Patients and tumor characteristics
A total of 28 patients with ACC were included in this
study. Patient characteristics are summarized in Table 1.
Overall, the median age was 47.4 +/−13.2 years ran-
ging from 19.8 to 73.7 years. Mean tumor size was
10.9 +/−4.4 cm ranging from 2.5 to 19 cm. The stage
at diagnosis was defined pathologically according to Inter-
national Union Against Cancer (UICC) and European
Network for the Study of Adrenal Tumors (ENSAT) sta-
ging systems [23]. UICC stage I, II, III and IV were found
in 1, 9, 3 and 11 patients, respectively, and ENSAT stage I,
II, III, IV were found in 1, 9, 4 and 10 patients, respect-
ively. Additionally, 19 patients developed metastasis dur-
ing the follow up period and 14 patients presented with
functional tumors at diagnosis.
In this cohort, 8 specimens were from metastasis and
20 from primary tumors. Among the metastatic speci-
mens, only one had metastatic disease at diagnosis. Others
had specimens collected at the time of relapse.
Correlation of PD-L1 expression and clinico-pathological
features
Overall, PD-L1 expression on tumor cell membrane was
considered positive in 3 of 28 patients (10.7%) (Figure 1).
On univiariate analysis, PD-L1 expression was not corre-
lated with stage (UICC and/or ENSAT), grade, or exces-
sive secretion of hormones (Table 2).
A total of 27 patients were evaluated for PD-L1 ex-
pression in tumor infiltrating mononuclear cells (TIMC).
The extent of TIMC were recorded as focal in 7 patients
(26%), mild in 9 patients (33.3%), moderate in 9 patients
(33.3%), and high in 2 patients (7.4%). For PD-L1 expres-
sion in TIMC, scores greater than zero were identified in
19 patients (70.4%). There was no significant correlation
between PD-L1 expression in TIMC and stage (UICC
and/or ENSAT), grade, or excessive hormone secretion
(Table 3).
We further explored the effect of PD-L1 expression
over other variables such as site of metastasis, number
of mitosis per 10 high-power fields, age or tumor size.
However, no association was found between any of these
parameters and PD-L1 expression in either tumor cell
membrane or TIMC (data not shown).
Correlation of PD-L1 expression and overall survival
Overall, 6 patients died during the follow up period.
Positive PD-L1 expression in tumor cell membrane was
not associated with 5-year survival (univariate analysis;
two-sided p = 0.65) (Figure 2).
Discussion
Multiple retrospective analyses described the correlation
between levels of PD-L1 expression and prognosis in
several malignancies [20]. Some of these studies in renal
cell carcinoma (RCC), breast cancer, and non-small cell
lung cancer (NSCLC), demonstrated that higher levels of
PD-L1 expression in tumor cells were associated with an
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unfavorable prognosis [24-26]. In contrast, higher PD-L1
expression on immune cells was associated with longer
OS in melanoma and metastatic urothelial carcinoma
[27,28]. To our knowledge, this is the first study to
characterize PD-L1 expression and its clinical signifi-
cance in ACC.
Tumor stage at diagnosis is the most important prog-
nostic factor in ACC [29]. However, different clinical
courses have been described among patients into the same
tumor stage. Some retrospective analyses have reported
that functional tumors may be associated with worse
prognosis [30]. In addition, few studies have established
histological or molecular markers, such as Ki67 index or
TP53 mutations, as predictors of poor prognosis and its
value still needs to be confirmed [31]. From a clinician
perspective, to investigate biomarkers that can predict re-
sponse to treatments may be important in the decision-
making process in the era of personalized medicine. In
our analysis, PD-L1 positivity was observed in approxi-
mately 11% of ACC cases and did not correlate with stage
at diagnosis (UICC or ENSAT), grade, and excessive se-
cretion of hormones. Furthermore, no correlations were
found between PD-L1 expression and survival at 5 years.
Some tumors are infiltrated by immune cells and it
can dynamically influence the host immune response
against tumor [32]. Interestingly, Willenberg and col-
leagues provided evidence of the involvement of immune
cells and interleukin-2 (IL-2) cytokine stimulation in the
formation of an adrenocortical tumor in a patient with
Cushing’s syndrome [33]. While little is known about
the immune microenvironment in ACC, these findings
may open new avenues on the understanding of tumor
biology and development of new treatment strategies.
The interaction between PD-1 and its ligand PD-L1
limits T cell activation in response to certain antigens in
order to prevent immune-mediated damage in healthy
tissue. Furthermore, chronic antigen exposure increases
the levels of PD-L1 expression, resulting in T cell “exhaus-
tion” and reduced immune control of tumor progression
[34]. Tumor cells have the ability to express PD-L1 as an
adaptive mechanism of resistance that can evade the im-
mune system, resulting in tumor growth and more aggres-
sive disease.
With the goal of restoring effective T cell responses,
the inhibition of immune checkpoints such as PD-1 or
PD-L1 has been considered attractive therapeutic targets
using monoclonal antibodies. A set of well conducted
clinical trials have reported encouraging clinical activity
on PD-1/PD-L1 blockade across multiple tumor types.
The first phase I clinical trial of nivolumab, an anti-PD-1
monoclonal antibody, showed significant clinical activ-
ity in RCC, melanoma, and NSCLC, leading to deeper
investigations [35]. Other agents targeting this pathway
have supported these early results [36]. In addition,
combinations of immunomodulatory agents have been
tested in different solid tumors and reported promising
results [37].
No biomarkers have been established to precisely select
patients for therapeutic strategies blocking the PD-1/PD-
L1 axis. Moreover, while several studies have reported that
Table 1 Patient characteristics
Characteristics
Total (N = 28)
No. of
patients %
Sex Male 13 46.4
Female 15 53.6
Stage at Diagnosis
(UICC)
I 1 4.2
II 9 37.5
III 3 12.5
IV 11 45.8
Missing 4 -
Stage at Diagnosis
(ENSAT)
I 1 4.2
II 9 37.5
III 4 16.6
IV 10 41.7
Missing 4 -
Grade Low 1 8.3
High 11 91.7
Missing 16 -
Metastatic disease Yes 19 67.9
No 9 32.1
Sites of Metastasis Local Recurrence 4 14.3
Lymph Node 8 28.6
Lung 10 35.7
Liver 8 28.6
Bone 2 7.1
Other 3 10.7
Functional Tumors at
Diagnosis
Yes 14 50
No 14 50
PD-L1 Expression on
Tumor Cell Membrane
<5% (negative) 25 89.3
≥5% (positive) 3 10.7
PD-L1 Expression in
Tumor Infiltrating
Mononuclear
Cells (TIMC)*
Score = 0
(negative)
8 29.6
Score > 0
(positive)
19 70.4
Mean +/− SD Min, Max
Age at Diagnosis
(years)
47.4 +/−13.2 19.8 -
73.7
Tumor size (cm) 10.9 +/−4.4 2.5 -19
Mitosis/10HPF 13.7 +/−13.5 0.2-50
*In 1 patient, the PD-L1 staining in TIMC was not assessable.
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PD-L1 expression in both tumor cell or tumor infiltrating
immune cells is a potential predictor of response to im-
munomodulatory agents, the meaning and significance of
PD-L1 expression in tumor cells or immune cells is still
being investigated [20]. Preliminary results from a phase I
study of an anti-PD-L1 inhibitor (MPDL3280A) in pa-
tients with advanced urothelial carcinoma showed re-
sponse rates of 52% in patients with PD-L1 positive in
immune cells vs. 14% in PD-L1 negative patients [38].
Interestingly, accumulating evidence shows that durable
responses can also occur in patients who do not express
PD-L1 on tumor cell membrane and/or tumor infiltrating
immune cells [39]. This raises important considerations
including tumor heterogeneity and tumor microenviron-
ment alterations that need to be investigated in further
studies.
Though this is the first study to date to evaluate the
prevalence and prognostic significance of PD-L1 expres-
sion in ACC, there are several limitations. First, the
retrospective nature of this analysis has led to missing
data which may result in selection bias. In addition, con-
sidering that ACC incidence is low, it is difficult to per-
form studies with large and homogeneous cohorts. In
our study, the sample size and the number of events in
each group according to PD-L1 positivity were very small,
limiting our ability to detect statistically significant
Figure 1 PD-L1 Expression in FFPE ACC Samples Stained with Anti-PD-L1 Antibody (clone 405.9A11). Positive membranous staining is
present in tumor cells in panel (a). In panel (b), tumor cells are negative, and TIMC are positive for PD-L1.
Table 2 Patient characteristics according to PD-L1 expression on tumor cell membrane
Characteristics (N = 28) % Positive tumor cell membrane
<5% (negative) (n = 25, 89.3%) n(%) 5% or more (positive) (n = 3, 10.7%) n(%) P-value*
UICC Stage** I/II 9(90) 1(10) -
III/IV 13(92.8) 1(7.2)
ENSAT Stage** I/II 9(90) 1(10) -
III/IV 13(92.8) 1(7.2)
Grade*** Low 1(100) 0(0) -
High 10(90.9) 1(9.1)
Functional Tumors at Diagnosis Yes 14(100) 0(0) 0.22
No 11(78.6) 3(21.4)
*Fisher’s Exact Test.
**Missing: 4.
***Missing: 12.
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differences between groups. At the same time, there may
be a missing-variable bias, since other clinico-pathological
features such as Ki67 were not available for the majority
of patients in this cohort. Furthermore, tumor heterogen-
eity is a confounding factor and differences between of
primary and metastasis still need to be investigated. In 2
patients from our series, we had the opportunity to review
primary and metastatic sites of disease. In one case, the
primary tumor and one met were evaluated; in the other
case the primary tumor plus 3 independent metastases
were compared. Interestingly, in both cases the same re-
sults regarding PD-L1 expression (positive or negative)
were observed in primary and metastatic samples
stained for PD-L1. In this study, we tried to minimize
the selection bias due to tumor heterogeneity by analyz-
ing whole tissue sections from surgical resections and
excluding needle biopsies. Finally, we focused on the
clinical significance of PD-L1 expression in either,
tumor cells and immune cells. However, the criteria de-
fining PD-L1 positivity (cut-offs) as well as the anti-
bodies used to stain for PD-L1 have varied among
different studies. Therefore, comparisons with other
studies should be done with caution and a more specific
definition of immune cells subtypes should be focus of
further studies. Although the same methodology used in
this analysis has been applied to other studies, the
methodology for PD-L1 staining should be standardized
to allow for reliable evaluation of PD-L1 expression and
comparison among differing cohorts [40].
Conclusions
In summary, ACC can express PD-L1 on both tumor
cell membrane and immune cells and it may represent a
potential target for therapeutic interventions. The current
progress in cancer immunotherapy warrants prospective
validation of our findings and further investigation of
Table 3 Patient characteristics according to PD-L1 expres-
sion on TIMC
Characteristics
(n = 27)
Tumor infiltrating
mononuclear cells
Score = 0
(negative)
(n = 8, 29.6%)
n(%)
Score > 0
(positive)
(n = 19, 70.4%)
n(%)
P-value*
UICC Stage** I/II 1(11.1) 8(88.9) 0.34
III/IV 5(35.7) 9(64.3)
ENSAT Stage** I/II 1(11.1) 8(88.9) 0.34
III/IV 5(35.7) 9(64.3)
Grade*** Low 0(0) 1(100) -
High 3(30) 7(70)
Functional Tumors
at Diagnosis
Yes 4(30.8) 9(69.2) -
No 4(28.6) 10(71.4)
*Fisher’s Exact Test.
**Missing: 4.
***Missing: 16.
Figure 2 PD-L1 expression on TIMC and 5-Year survival rate (univariate analysis).
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agents blocking the PD-1/PD-L1 pathway in this aggres-
sive disease.
Methods
Patients and samples
Twenty-eight patients with ACC treated surgically at
Dana-Farber Cancer Institute or Brigham and Women’s
Hospital were retrospectively selected. Formalin fixed
paraffin-embedded (FFPE) blocks from primary tumors
or metastases were retrieved, and for each patient one
representative tumor block was selected for analysis by a
genitourinary pathologist. Baseline clinico-pathological
characteristics such as age, gender, tumor size, grade, stage
using UICC and ENSAT staging systems, hormone-related
symptoms at clinical presentation, as well as follow up
data were retrospectively collected for all patients. Patients
who presented with Cushing’s syndrome, virilization, or
feminilization were classified as functional tumors. This
study received Institutional Review Board approval before
tumor staining and data acquisition.
Immunohistochemistry
PD-L1 expression was evaluated by immunohistochemis-
try (IHC) using a mouse monoclonal anti-PD-L1 antibody
(405.9A11) developed in Dr. Gordon Freeman’s laboratory
at Dana-Farber Cancer Institute. The immunohistochemi-
cal assay was validated using FFPE cell line controls known
to be positive or negative for PD-L1 expression by flow cy-
tometry [41]. Four micron-thick tumor sections were
stained with an anti-PD-L1 antibody at a concentration of
3.25 ug/ml on a Benchmark XTautostainer (Ventana Med-
ical System, Tucson, AZ) with standard antigen retrieval
(CC1 buffer, pH8.0, #950-124, Ventana). UltraView
Universal DAB Detection kit (#760-500, Ventana) was
used according to the manufacturer’s instruction. Coun-
terstaining was performed as part of the automated stain-
ing protocol using hematoxylin (#760-2021, Ventana).
After staining, slides were then washed in soap water and
distilled water, dehydrated in graded alcohol and xylene,
mounted, and cover slipped.
CD45 immunostaining was performed on adjacent
four micron-thick tumor sections, which were initially
deparaffinized, rehydrated and heated with a pressure
cooker to 125°C for 30 seconds in citrate buffer for
antigen retrieval and then incubated with peroxidase
(Dako #S2003, Carpinteria, CA) and protein blocking
reagents (Dako #X0909) each for 5 minutes. Sections
were then incubated with anti-CD45 (1:100, Dako, clone
2B11 + PD7/26) antibody for 1 hour at room temperature
followed by incubation with the Dako EnVision + System
HRP labeled polymer anti-mouse (Dako #K4001) for
30 minutes. All sections were developed using the DAB
chromogen kit (Dako K3468) for 2 minutes and then
lightly counterstained with hematoxylin.
Scoring of PD-L1 expression on tumor cell membrane
For each sample, the percentage of tumor cells with PD-L1
expression on the cell membrane was estimated by two in-
dependent genitourinary pathologists who were blinded to
clinical outcomes.
Scoring of PD-L1 expression in Tumor Infiltrating
Mononuclear Cells (TIMC)
TIMC were identified on the basis of IHC positivity for
CD45, a pan-leukocyte marker expressed in lymphocytes,
macrophages and dendritic cells [42,43]. The extent of
TIMC was recorded as absent (0), focal (1), mild (2), mod-
erate (3) and marked (4). The percentage of PD-L1 expres-
sion in TIMC was evaluated semi-quantitatively according
to three categories: 0% = 0, <5% = 1, and ≥5% = 2. An ad-
justed score was then calculated multiplying the percentage
of TIMC that stained positive for PD-L1 and the extent of
infiltrating immune cells, as previously reported [44].
Staining for PD-L1 was not performed in one patient in
whom the available specimen was from a lymph node
given that tumoral and non-tumoral immune cells could
not be distinguished.
Statistical analysis
In this exploratory biomarker study, the pre-defined pri-
mary objective of this study was to characterize levels of
PD-L1 expression on tumor cell membrane and TIMC in
patients with ACC. Secondary endpoints were the correl-
ation of PD-L1 expression with clinico-pathological fea-
tures as well as 5-year survival rates. Five-year survival
rate was defined as the time period between date of diag-
nosis and the date of death, or censored at 5 years after
diagnosis. PD-L1 tumor positivity on tumor cells was de-
fined as ≥5% tumor cell membrane staining. For PD-L1
expression in TIMC, any score greater than zero was con-
sidered positive.
Statistical analyses were performed using SAS (version
9.2; SAS Institute Inc., Cary, NC, USA). Descriptive data
are presented as mean and standard deviation (SD), or
percentage. Comparisons between PD-L1 expression and
clinico-pathological features were evaluated using Fisher’s
exact test for categorical variables and unpaired t-test for
continuous variables. Kaplan-Meier method estimated the
distribution of 5-year survival rates by PD-L1 positivity.
The association of 5-year survival rates with PD-L1 ex-
pression (negative vs. positive) was assessed by log-rank
test and univariate Cox proportional regression analysis.
Multivariate analysis were to be performed only if
p-values were <0.05, considered statistically significant.
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